Prostate cancer (PCa) is the second most frequently diagnosed cancer among men worldwide, with almost 1.3 million new cases and 360,000 deaths in 2018. As it has been estimated, its mortality will double by 2040, mostly in countries with limited resources. These numbers suggest that recent trends in deep learning-based computer-aided diagnosis could play an important role, serving as screening methods for PCa detection. These algorithms have already been used with histopathological images in many works, in which authors tend to focus on achieving high accuracy results for classifying between malignant and normal cases. These results are commonly obtained by training very deep and complex convolutional neural networks, which require high computing power and resources not only in this process, but also in the inference step. As the number of cases rises in regions with limited resources, reducing prediction time becomes more important. In this work, we measured the performance of current state-of-the-art models for PCa detection with a novel benchmark and compared the results with PROMETEO, a custom architecture that we proposed. The results of the comprehensive comparison show that using dedicated models for specific applications could be of great importance in the future.
Keywords: artificial intelligence; benchmark; convolutional neural networks; deep learning; performance evaluation; prostate cancer.